Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Return on Capital Employed (2016 - 2025)

Spyre Therapeutics' Return on Capital Employed history spans 10 years, with the latest figure at 0.36% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 9.0% year-over-year to 0.36%; the TTM value through Dec 2025 reached 0.36%, up 9.0%, while the annual FY2025 figure was 0.33%, 16.0% up from the prior year.
  • Return on Capital Employed reached 0.36% in Q4 2025 per SYRE's latest filing, up from 0.45% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 2.56% in Q2 2023 to a low of 1.61% in Q1 2023.
  • Average Return on Capital Employed over 5 years is 0.58%, with a median of 0.6% recorded in 2021.
  • Peak YoY movement for Return on Capital Employed: soared 367bps in 2023, then tumbled -292bps in 2024.
  • A 5-year view of Return on Capital Employed shows it stood at 0.66% in 2021, then tumbled by -92bps to 1.27% in 2022, then rose by 21bps to 1.0% in 2023, then skyrocketed by 55bps to 0.45% in 2024, then grew by 21bps to 0.36% in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Return on Capital Employed are 0.36% (Q4 2025), 0.45% (Q3 2025), and 0.45% (Q2 2025).